Carisma Therapeutics, Inc. (CARM) Research

Carisma Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to pioneering chimeric antigen receptor (CAR) macrophage therapies specifically designed to target solid cancerous growths. Its therapeutic approaches are instrumental in modulating both the inherent and acquired functions of the immune system. The company's sophisticated platform draws upon breakthroughs in macrophage science, CAR design, and cell-based treatments to address various human ailments. Notably, Carisma Therapeutics maintains a key strategic alliance with Moderna Inc. Incorporated in 2016 and headquartered in Philadelphia, Pennsylvania, the organization was initially established as CARMA Therapeutics Inc., before rebranding to its current name, Carisma Therapeutics, Inc., in May of 2017.

Market snapshot

Symbol
CARM
Price
$0.02
Day change
+187.88%
Market cap
$795.1K
P/E ratio
0.10x
52-week range
0.0001-0.56
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$6.00

Peer companies

  • Aspire Biopharma Holdings, Inc. (ASBP)
  • CDT Equity Inc. (CDT)
  • Enveric Biosciences, Inc. (ENVB)
  • Indaptus Therapeutics, Inc. (INDP)
  • Jasper Therapeutics, Inc. (JSPR)
  • Onconetix, Inc. (ONCO)
  • Revelation Biosciences, Inc. (REVB)
  • Salarius Pharmaceuticals, Inc. (SLRX)

Recent insider activity

  • Klichinsky Michael — M-Exempt (56982 shares) on 2025-10-07
  • Klichinsky Michael — S-Sale (56982 shares) on 2025-10-07
  • Klichinsky Michael — M-Exempt (56982 shares) on 2025-10-07
  • Klichinsky Michael — S-Sale (165000 shares) on 2025-10-01
  • Klichinsky Michael — S-Sale (200000 shares) on 2025-10-02

Open Carisma Therapeutics, Inc. (CARM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.